MIRA
INFORM REPORT
|
Report Date : |
28.11.2007 |
IDENTIFICATION
DETAILS
|
Name : |
TRIVITRON DIAGNOSTICS PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Trivitron Sapthagiri Bhavan, No. 15 Street, Abhiramapuram, Chennai –
600018, Tamilnadu. |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2007 |
|
|
|
|
Date of Incorporation : |
18.05.1998 |
|
|
|
|
Com. Reg. No.: |
18-40515 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U85110TN1998PTC040515 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
CHET07271F /
CHET07756A |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACT9378H |
|
|
|
|
Legal Form : |
Private Limited
Liability Company |
|
|
|
|
Line of Business : |
Manufacturers of
Diagnostic Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Aa |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
Maximum Credit Limit : |
USD 289228 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well
established and reputed company having fine track. Trade relations are fair.
Financial position is good. Payments are usually correct and as per
commitments. The company can
be considered good for any normal business dealings. It can be regarded as a
promising business partner in a medium to long run. |
LOCATIONS
|
Registered Office/Factory: |
Trivitron Sapthagiri Bhavan, No. 15, IV Street, Abhiramapuram, Chennai
– 600018, Tamilnadu, India |
|
Tel. No.: |
91-44-24985050 /
28522216 / 28594817/ 24985151/ 5656 |
|
Fax No.: |
91-44-24985757 /
28548997 |
|
E-Mail : |
|
|
Website: |
|
|
|
|
|
Corporate Office : |
Trivitron Group of Companies. 15, IVth Street,
Abhiramapuram, Chennai - 600 018.India. |
|
Tel. No.: |
+91 - 44 - 2498 5050 (6 lines) |
|
Fax No.: |
91 - 44 - 2498 5757 / 2467 2782 |
|
E-Mail : |
|
|
|
|
|
Regional Offices: |
CHENNAI (Renal Care) NEW DELHI MUMBAI MUMBAI ( Diagnostics ) KOLKATA BANGALORE HYDERABAD PONDICHERRY |
|
|
|
|
Overseas Offices: |
SRI LANKA DUBAI |
|
|
|
|
Branches : |
NAGPUR THRISSUR AHMEDABAD COIMBATORE COCHIN PUNE CHANDIGARH JAIPUR LUCKNOW |
DIRECTORS
|
Name : |
Dr. G. S. K. Velu
|
|
|
Designation : |
Managing Director
|
|
|
Address : |
No. 25 (Old No.
13), 1st Main Road, Cit Colony, Mylapore, Chennai – 600 004,
Tamilnadu, India. |
|
|
Date of Birth/Age : |
30.06.1967 |
|
|
Date of Appointment : |
28.01.1999 |
|
|
|
|
|
|
Name : |
Mrs. Subha K Velu
|
|
|
Designation : |
Director |
|
|
Address : |
No. 25 (Old No.
13), 1st Main Road, Cit Colony, Mylapore, Chennai – 600 004,
Tamilnadu, India. |
|
|
Date of Birth/Age : |
25.10.1972 |
|
|
Date of Appointment : |
27.01.1997 |
|
|
|
|
|
|
Name : |
Mr. Sameer D
Saral |
|
|
Designation : |
Director |
|
|
Address : |
C 3, Kosala No.
14, Srinivasa Road, T. Nagar, Chennai – 600 017, Tamilnadu, India. |
|
|
Date of Birth/Age : |
17.06.1963 |
|
|
Date of Appointment : |
27.01.1997 |
|
|
|
|
|
|
Name : |
Mr. Chandrasekhar Kandasamy |
|
|
Designation : |
Director |
|
|
Address : |
Villa 17, phase I, palm Meadows, Airports Whitefield Road, Bangalore –
560 066, Karnataka |
|
|
Date of Birth/Age : |
31.01.1967 |
|
|
Date of Appointment : |
31.10.2007 |
|
|
|
|
|
|
Name : |
Mr. James Frederick Savage |
|
|
Designation : |
Director |
|
|
Address : |
8A Block 18, Baguio Villas, 555 Victoria Road, Pok Fu Lam Hong Kong |
|
|
Date of Birth/Age : |
18.04.1969 |
|
|
Date of Appointment : |
31.10.2007 |
|
|
|
|
|
|
Name : |
Mr. Velu Kulandai Subbulakshmi |
|
|
Designation : |
Director |
|
|
Address : |
25, first Main road, CIT Colony , Mylapore, Chennai – 600 004, Tamil
Nadu |
|
|
Date of Birth/Age : |
25.10.1972 |
|
|
Date of Appointment : |
18.05.1998 |
|
KEY EXECUTIVES
|
Name : |
Mr. K Venugopalan |
|
Designation : |
Company Secretary |
|
Address : |
1st Floor, 22/3 Venkatarishna Road, Mandaveli, Chennai – 600 020 |
|
Tel No: |
91-44-42815423 |
|
Mobile: |
91-9840819356 |
|
Email: |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
|
Names of Shareholders |
|
No. of Shares |
|
Dr. GSK Velu |
|
620630 |
|
Mr. Sameer D Saral |
|
100 |
|
Mr. Sudha K Velu |
|
100 |
|
|
Total
|
620830 |
Equity Shares Breakup (Percentage of Total Equity):
|
Sr No. |
Category |
Percentage |
|
1 |
Directors or relatives of directors |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturers of Diagnostic
Products |
|
|
|
|
Products : |
v
Immulite
Analyser v
Cell Counter
v
Blood Gas
Analyser v
Celly-Haematology
Analyser v
Others-Spares
& Consumables |
|
|
|
|
Exports to : |
Sri Lanka, Nepal,
Bangladesh |
|
|
|
|
Imports from : |
Europe, USA,
Japan |
|
|
|
|
Terms : |
|
|
Selling : |
L/C |
|
|
|
|
Purchasing : |
L/C DA |
GENERAL
INFORMATION
|
Suppliers : |
v
Hamilton
Medical , Switzerland v
Fresenius
Medical, Germany |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Customers : |
v
Sri
Ramchandra Medical College, Porur, Chennai v
All India
Institute of Medical Sciences, New Delhi
|
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Employees: |
150 |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Bankers: |
· ING Vysya Bank Limited, Address: 13/1, Karpagambal Nagar, Mylapore
Branch, Chennai – 600 004. · HDFC Bank Limited Address: Chennai – 600 002 |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Facilities : |
|
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Banking Relations : |
Good |
||||||||||||||||||
|
|
|
||||||||||||||||||
|
Auditors : |
R Subramanian and
Company Chartered
Accountants |
||||||||||||||||||
|
Address: |
36, New No. 6,
Krishnaswamy Avenue Mylapore, Chennai – 600 004. |
||||||||||||||||||
|
Tel. No.: |
91-44-24992261/
1347/ 4231 |
||||||||||||||||||
|
Fax No.: |
91-44-24991408 |
||||||||||||||||||
|
Email: |
|||||||||||||||||||
|
|
|
||||||||||||||||||
|
Associates/Subsidiaries : |
Trivitron Medical
Systems Private Limited |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
850000 |
Equity shares |
Rs. 10/- each |
Rs. 8.500 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
620830 |
Equity shares |
Rs. 10/-
each |
Rs. 6.208
millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
6.208 |
6.208 |
4.208 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
66.099 |
42.233 |
24.688 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
72.307 |
48.441 |
28.896 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
32.355 |
9.483 |
4.995 |
|
|
2] Unsecured Loans |
2.096 |
0.992 |
1.433 |
|
|
TOTAL BORROWING |
34.451 |
10.475 |
6.428 |
|
|
DEFERRED TAX LIABILITIES |
1.625 |
1.384 |
1.340 |
|
|
|
|
|
|
|
|
TOTAL |
108.383 |
60.300 |
36.664 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
44.631 |
34.196 |
25.992 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
6.293 |
2.057 |
2.057 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
20.493
|
14.550 |
10.519 |
|
|
Sundry Debtors |
155.775
|
109.921 |
59.756 |
|
|
Cash & Bank Balances |
19.952
|
7.475 |
20.493 |
|
|
Other Current Assets |
0.322
|
0.301 |
0.149 |
|
|
Loans & Advances |
18.848
|
15.084 |
12.097 |
|
Total
Current Assets |
215.390
|
147.331 |
103.014 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
144.339
|
111.701 |
85.697 |
|
|
Provisions |
13.592
|
11.583 |
8.702 |
|
Total
Current Liabilities |
157.931
|
123.284 |
94.399 |
|
|
Net Current Assets |
57.459
|
24.047 |
8.615 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
108.383 |
60.300 |
36.664 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
|
Sales Turnover |
408.156 |
314.928 |
227.747 |
|
|
Other Income |
16.739 |
6.271 |
6.955 |
|
|
Total Income |
424.895 |
321.199 |
234.702 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
37.702 |
28.676 |
24.536 |
|
|
Provision for Taxation |
13.835 |
11.132 |
9.111 |
|
|
Profit/(Loss) After Tax |
23.867 |
17.544 |
15.425 |
|
|
|
|
|
|
|
|
Earnings in Foreign Currency : |
|
|
|
|
|
|
Export Earnings |
10.505 |
14.348 |
0.131 |
|
|
Commission Earnings |
1.364 |
0.843 |
6.182 |
|
Total Earnings |
11.869 |
15.191 |
6.313 |
|
|
|
|
|
|
|
|
Import Value |
275.716 |
194.782 |
142.986 |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Cost of Goods Sold |
291.224 |
218.657 |
151.500 |
|
|
Administrative Expenses |
88.770 |
71.085 |
56.964 |
|
|
Financial Charges |
2.029 |
0.955 |
0.868 |
|
|
Depreciation & Amortization |
5.170 |
1.826 |
0.834 |
|
|
Other Expenditure |
[7.199] |
[2.781] |
1.702 |
|
Total Expenditure |
379.994 |
289.742 |
208.464 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
PAT / Total Income |
(%) |
5.61
|
5.46 |
6.57 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
9.23
|
9.10 |
10.77 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
14.49
|
15.79 |
19.01 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.52
|
0.59 |
0.84 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
2.66
|
2.76 |
3.48 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.36
|
1.19 |
1.09 |
LOCAL AGENCY
FURTHER INFORMATION
|
Corporation identity number or foreign company registrations number of
the company |
U85110TN1998PTC040515 |
|
Name of the company |
TRIVITRON DIAGNOSTICS PRIVATE LIMITED |
|
Address |
Trivitron Sapthagiri Bhavan, No. 15 Street, Abhiramapuram, Chennai –
600018, Tamilnadu. |
|
This Form is for |
Creation of charge |
|
Type of Charges |
Movable property |
|
Particular of the charge holder
|
HDFC Babnk Liimted Address: HDFC Bank Houses Senapati Bapat
Marg, Lower Parel, Mumbai – 400 013 Email ID: srinivasan.venkatatraman@hdfcbank.com
|
|
Nature or description of the instrument creating charge |
Memorandum relating to hypothecation of
machinery dated 1st August 2007 |
|
Date of the instrument creating charge |
01.08.2007 |
|
Amount Secure by the charge |
Rs. 100.000 millions |
|
Brief of the principal terms and conditions and extent and operation
of the charge |
Rate of Interests: Any such rate as may be advised to the
company from time to time in respect of the credit facilities. Term of repayment: Repayable on Demand Margin: As may be prescribed by the bank from time
ot time for the credit facilities. Extent nad operation of charge: Hypothecation by way first exclusive
charge in favour of HDFC Bank Limited on all the movable Plant and Machinery
of the company both present and future in respect of credit facilities
granted / to be granted to the group company M/s. Trivitron Medical Systems
Peivate4 limited total facilities aggregating to Rs. 100.000 millions. |
|
Shorts particulars of the
Property charged |
Hypothecation by way of First Exclusive
Charge on all movable plant and machinery of the company both present and
future (more particularly described in the attachment) |
|
Name of the
company |
TRIVITRON DIAGNOSTICS PRIVATE LIMITED |
||||||||||
|
Presented
By |
Sri G S K Velu ,
Managing Director |
||||||||||
|
1) Date and
description of instrument creating the change |
08.06.2000 –
agreement fro hypothecation of stock in trade, machinery, Book debts, bills
and all other movables 08.06.2000 – General
Counter Guarantee and indemnity covering several guarantees within the
sanctioned guaranteed Limit. 08.06.2000-
letter of hypothecation to secure time to time Trust Loan against goods. |
||||||||||
|
2) Amount secured
by the charge/amount owing on the securities of charge |
|
||||||||||
|
3) Short particular
of the property charged. If the property acquired is subject to charge, date
of the acquired of the property should be given |
· Hypothecation of diagnostics Equipment / Consumable in trade · Hypothecation of diagnostics equipment / Consumable covered under Import LCs/ BGs · Counter guarantee for BGs. |
||||||||||
|
4) Gist of the
terms and conditions and extent and operation of the charge. |
Interest for overdraft at 16.5% p.a +
interest tax Margin 40% for overdraft Commission as per circular Instruction for
BG and LC Margin 25% in Term Deposits and Tenor 90
days After sight for LC Collaterally to be secured by residential
flat No. 4, 1st Floor, Krishna Apartments, 2A Warren Road,
Mylapore, Chennai property standing in the name of Smt. G Gomathi Personal guarantee of directors and
property owners OD SIT – limit are valid upto 14.04. 2001 |
||||||||||
|
5) Name and
Address and description of the person entitled to the charge. |
ING Vysya Bank Limited Address: 13/1, Karpagambal Nagar,
Mylapore, Chennai -4 |
||||||||||
|
6) Date and brief description of instrument
modifying the charge |
30.06.2004 Agreement for
hypothecation of stock in trade, machinery, book debts, bills and all other
movables. |
||||||||||
|
7) Particulars of
modifications specifying the terms and conditions or the extent of operations
of the charge in which modification is made and the details of the
modification. |
Modification is
consequent to charging of the entire fixed of the company to secure the adhoc
Import LC limit of Rs. 36.000 millions and Adhoc BG limit of Rs. 3.600
millions sanctioned to group company Trivitron Medical Systems P. Limited. |
|
Name of the
company |
TRIVITRON
DIAGNOSTICS PRIVATE LIMITED |
||||||||||||
|
Presented
By |
Mr. Dr.
G. S. K. Velu, Managing Director |
||||||||||||
|
1) Date and
description of instrument creating the change |
08.06.2000 Agreement for
Hypothecation of Stock in Trade, Machinery, Book Debts, Bills and all other
movables. 08.06.2000 General Counter
Guarantee & Indemnity covering several Guarantee with in the sanctioned
Guarantee limit. 08.06.2000 Letter of
Hypothecation to secure time to time Trust Loan against goods. |
||||||||||||
|
2) Amount secured
by the charge/amount owing on the securities of charge |
|
||||||||||||
|
3) Short
particular of the property charged. If the property acquired is subject to charge,
date of the acquired of the property should be given |
Hypothecation of
Diagnostic Equipment /Consumables in Trade Hypothecation of
Diagnostic Equipment/ Consumables covered under Import LCs/ BGs. Counter Guarantee
for BGs. |
||||||||||||
|
4) Gist of the terms
and conditions and extent and operation of the charge. |
1)
Interest for
Overdraft at 16.5% p.a.+ Interest Tax. 2)
Margin 40%
for Overdraft 3)
Commission
as per circular instruction for BG & LC. 4)
Margin 25%
in Term Deposit & tenor 90 days after sight for LC 5)
Collaterally
to be secured by residential flat at No: 4, 1st Floor, Krishna
Apartments, 2A Warren Road, Mylapore, Chennai property standing in the name
of smt. G. Gomathi. 6)
Collaterally
to be secured by property 6.41 acres pf land with cottages called Horton Bungalow
T.S. No. 5/1 & 5/2 ward c, Block 8, Avery Avenue, Kodaikanal, property
standing in the name of Sri V. R. Venkatachalam. 7)
Personal
Guarantee of Directors & Property owners. 8)
OD SIT –
Limit are valid up to 14.04.2001. |
||||||||||||
|
5) Name and
Address and description of the person entitled to the charge. |
ING Vysya Bank Limited, 13/1, Karpagambal Nagar, Mylapore Branch, Chennai – 600 004. |
||||||||||||
|
6) Date and brief description of instrument
modifying the charge |
Agreement for
Hypothecation of Stock in Trade, Machinery, Book Debts, Bills and all other
movables. |
||||||||||||
|
7) Particulars of
modifications specifying the terms and conditions or the extent of operations
of the charge in which modification is made and the details of the
modification. |
Modification is consequent
to charging of the entire Fixed of the company to secure the Adhoc Import LC
limit of Rs. 36.000 Millions and Adhoc BG limit of Rs. 3.600 Millions
sanctioned to group company Trivitron Medical Systems P. Ltd. |
Fixed Assets:
· Machineries and Equipments,
· Furniture & Fittings,
· Buildings & Interior Decoration,
· Vehicles,
· Computers
· Capital work in progress etc.
WEBSITE DETAILS:
VISION
To dynamically understand and
analyze the Medical Devices, Clinical
Diagnostic Equipment and Medical Consumables markets across India and neighbouring countries and
to cater to these needs indigenously and by collaborating with the best
multinational medical technology companies in the world.
PROFILE
Since its inception, Subject has grown at a steady pace to become the largest
medical technology company of Indian origin. And one amongst the Top 10
Medical Technology Brands in India.
Subject specializes in a
comprehensive range of medical device solutions covering the fields of imaging, cardiology, nephrology,
critical care, orthopaedics, anaesthesiology, intensive care, obstetrics and
gynaecology, radiology, urology, ophthalmology, gastroenterology, microbiology,
biochemistry, haematology, immunology, molecular biology, blood banking,
surgery, home care and geriatrics.
Their main focus is to help the
Indian markets identify their requirements, provide them a host of
international brands and indigenous options to choose from and aid them get
maximum value out of these brands through excellent service support and
continuous medical knowledge initiatives. They corroborate their commitment to
quality by associating with only the top international brands in the industry.
Their principal partners include names like Aloka, Fresenius, DPC, Hamilton, Richard Wolf
and Arthrex -
brands synonymous with their fields of specialisation, worldwide.
With 18 branch offices, over 100
dealers spread across the country and a 24/7 manned help line they try to make you feel every installation comes
with its own dedicated support team. So you know that you are never more than a
phone call away from the Trivitron smile.
Every member of Subject is handpicked as much for their technical skills as
for their personality and service motivation. They train them to be positive
and always willing to go out of the way to solve the problems.
No wonder they have a client retention rate of
almost 90% - testimony to their service claims.
Their unique combination of resources,
values and experience also enables them to offer cutting-edge, turnkey
solutions for the healthcare sector.
This includes consultancy services for setting up hospitals, nursing homes, clinical
laboratories and research centres.
Subject has plans to diversify
further into medical instrumentation and hospital services to remain in sync
with their vision of becoming the complete partner in healthcare facilitation.
ACCREDITION
All their products have USA FDA Accredition, CE Certification, and ISO Certification for their quality objectives.
Started representing
Hamilton Medical AG in
1997, after they had been here for 10 years and had only one major installation
- Their ventilators are now a part of every major medical teaching institute
and corporate hospital in the country.
Have successfully executed huge orders like US $ 1.7 million order
of HIV kits for NACO and US $ 500,000 order of Ventilators for PGIMER, Chandigarh.
Have become the one
source dialysis solution provider for Apollo
Group across India.
Introduced and
stabilized Aloka Colour Doppler
product line in India.
Are market leaders
in Dialysis and Arthroscopy.
No.1 Immunoassay supplier in India - have
a presence in every referral lab of repute in the country.
Have added a Neurology product line.
Have added Endoscopy and Physiotherapy
product lines.
Have added high end imaging products to their
product basket as well.
Since its inception,
Subject has grown at a steady pace to become one of the top 5
medical technology companies in India.
Some of their prominent corporate customer includes:
Government hospitals:
·
AIIMS (NewDelhi)
·
JJ Hospital, KEM
Hospital (Mumbai)
·
JIPMER (Pondicherry)
·
Nizam's (Hyderabad)
·
PGI (Chandigarh)
·
SGPGI (Lucknow)
Private Hospitals like:
·
Apollo group
(across India)
·
B.M.Birla
(Kolkata)
·
Breach Candy
Hospital (Mumbai)
·
Hinduja's
hospitals (Mumbai)
·
Mallya Hospital
(Bangalore)
·
Manipal
Hospital (Bangalore)
Teaching Institutes like:
·
CMC (Vellore)
·
MS Ramiah
Hospital (Bangalore)
·
Sri Ramachandra
Medical College (Chennai)
and large referral laboratories like SRL Ranbaxy, Metropolis, Nicholas Piramal, Vimta Path Labs and Dr.Lal's
Path Labs.
Subject has presence
across India, Srilanka, Nepal, Bangladesh, Maldives, Mauritius, Seychelles etc.
and all the major institutions across India use atleast one of Trivitron's Products. Medical technology strides boldly into the future, it is becoming
increasingly critical for healthcare service providers to stay abreast.
Added to the ever-changing demographics, an increasing population and spiraling
costs a reliable technology partner becomes invaluable.
Trivitron Projects looks to be just that.
A company with the muscle of international brands and a heart that's all
India !
Trivitron Projects is
that partner who comes into every project bringing expertise on technology, equipment, protocol, spatial dynamics and of course cost effectiveness.
They make this possible through their teams of highly qualified professionals
led by people with over thirty years of
experience in the fields of marketing and medical technology.
Trivitron Projects has
experience setting up complete
diagnostic labs, fully equipped Operation Theatres, state-of-the-art cardiac
care centres, high end ICUs, Imaging centres and Physiotherapy Clinics.
Their quality standards are vetted by their presence in most of the leading
healthcare institutions across the country. Some of the facilities where they
have executed projects include:
Nationwide:
Apollo Hospital Group Turnkey for entire
dialyser needs of Apollo Hospital Group , Clinical Laboratory package for
IMMULITE Analyser etc
In the South:
·
Sri Ramachandra
Medical College Hospital ( ICU / OPERATION ROOM/ DIALYSER )
·
Malar Hospital (
Clinical Laboratory )
·
Jawaharlal Institute of
Post Graduate Medical Education and Research Hospital ( Complete ICU
Ventilation )
·
K.G. Hospital (
Dialyser )
·
Christian Medical
College Hospital ( Dia / CL / ICU Complete package )
·
Mallya Hospital ( C.
LAB / DIA / ICU )
·
Manipal Hospital (
ICU Equipment Package )
·
MS Ramiah Hospital ( C Lab / Dia / Imaging center )
In the West:
·
PD Hinduja National Hospital ( Dia / ICU Equipment package )
·
Bombay Hospital ( Dialyser clinic for indoor facility )
In
the North:
·
All India Institute of Medical Sciences ( Clinical
package for cardio and neuro center )
·
Post Graduate Institute of Medical Sciences ( ICU Ventilation
package)
In
the East:
·
Suraksha Hospital ( Imaging / CL
PACKAGE )
Note : DIA :
Dialyser clinic
CL / C LAB : Clinical Laboratory
· And the Apollo Hospitals Group across India and neighbouring countries.
· All big names, All institutions famous for their penchant for quality healthcare. All Trivitron Customers.
· ITM University Awards for Corporate Excellence
Beloved
Managing Director Dr Velu
has been nominated and selected by a team of Top Management Professionals to
receive ITM University Awards for Corporate Excellence title with a Citation
and a Trophy. Prof. P V Ramana, Chairperson, ITM University will be confer this
award of esteem to Dr Velu.
ITM University, a
dynamic group founded under the Iconic and Visionary Leadership of Prof. P V
Ramana, which has achieved the Spirit of Excellence in the truest sense of the
term. The ITM Group of Business Schools has grown from one Business School in
Mumbai, to 7 campuses. Starting with a 2 year fulltime MBA program in 1991, The
ITM Group of Business Schools is currently conducting 15 programs, in a broad
range of fields including Financial Markets, Retail, Pharmaceuticals,
Healthcare, Risk Management, Human Resources etc
ITM University Awards for Corporate Excellence is conferred on professionals
who have achieved tremendously in the fields they represent. They are role
models, cheer leaders, nurturer of talents and professionals with a TRACK RECORD.
This year is especially challenging with India Shining for Corporate Czars and
Leaders, who believe in “MAD” approach - which is Making a Difference.
DPC AWARD FOR TRIVITRON'S HIGHEST SALES OF
IMMUULITE1000 INSTRUMENTS.
Trivitron Bags award
for highest sales of the Immulite 1000 instruments (2006). Presented by Dr.
Doug Olson, President, DPC ISD, Cirrus, New Jersey at the Annual Banquet of
International Distributors Meeting 2006, the award acknowledged the efforts of
the Trivitron Diagnostics division in achieving the highest sales for the year
2006. The first award in the six years since it began the DPC business,
Trivitron stands tall, breaking new grounds and achieving new heights. An
accomplishment that would have been truly impossible without the committed and
dedicated efforts of their team in the Diagnostics Division.
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or anti-terrorism
sanction laws or whose assets were seized, blocked, frozen or ordered forfeited
for violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.39.85 |
|
UK Pound |
1 |
Rs.82.61 |
|
Euro |
1 |
Rs.59.21 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
8 |
|
PAID-UP CAPITAL |
1~10 |
8 |
|
OPERATING SCALE |
1~10 |
8 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
8 |
|
--PROFITABILIRY |
1~10 |
8 |
|
--LIQUIDITY |
1~10 |
8 |
|
--LEVERAGE |
1~10 |
8 |
|
--RESERVES |
1~10 |
8 |
|
--CREDIT LINES |
1~10 |
8 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
72 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|